IDEXX Laboratories, Inc.
IDXX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -7.41 | 1.61 | 2.64 | -5.54 |
| FCF Yield | 0.73% | 0.35% | 0.61% | 0.66% |
| EV / EBITDA | 130.65 | 107.95 | 99.61 | 115.68 |
| Quality | ||||
| ROIC | 10.22% | 10.86% | 9.56% | 8.28% |
| Gross Margin | 61.83% | 62.62% | 62.44% | 59.80% |
| Cash Conversion Ratio | 1.47 | 0.63 | 0.98 | 1.21 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.12% | 4.74% | 4.65% | 4.99% |
| Free Cash Flow Growth | 144.81% | -27.07% | -6.66% | 16.03% |
| Safety | ||||
| Net Debt / EBITDA | 0.12 | 2.62 | 2.55 | 2.34 |
| Interest Coverage | 33.30 | 32.95 | 41.29 | 34.90 |
| Efficiency | ||||
| Inventory Turnover | 1.08 | 1.06 | 0.95 | 1.00 |
| Cash Conversion Cycle | 103.61 | 113.72 | 120.66 | 115.73 |